Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
Allan LiptonMilton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, USAAbstract: Bisphosphonates inhibit osteoclast-mediated bone resorption, thereby inhibiting the release of growth factors necessary to promote cancer cell growth, differentiation, and tumor formation in bone....
Guardado en:
Autor principal: | Allan Lipton |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a5d614df33a3424abd4785a12817b187 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
por: Bauer M, et al.
Publicado: (2012) -
Decreased risk of breast cancer associated with oral bisphosphonate therapy
por: Mathew A, et al.
Publicado: (2012) -
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
por: Neelima Vidula, et al.
Publicado: (2021) -
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
por: Jamil MO, et al.
Publicado: (2017) -
Recent advances in the development of breast cancer vaccines
por: Milani A, et al.
Publicado: (2014)